Oculis Holding AG (OCS) Common Equity (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Common Equity of $251.1 million for Q1 2026, up 38.83% year-over-year from $180.9 million in Q1 2025, and up 2.37% quarter-over-quarter from $245.3 million in Q4 2025.
Oculis Holding AG (OCS) Common Equity (2021 - 2026) Analysis & Trends
Oculis Holding AG's Common Equity history runs 6 years deep, the most recent figure standing at $251.1 million for Q1 2026.
- In Q1 2026, Common Equity rose 38.83% year-over-year to $251.1 million; the TTM figure through Mar 2026 stood at $251.1 million (up 38.83% YoY), while the FY2025 annual figure was $236.5 million, up 183.51% from the prior year.
- Common Equity for Q1 2026 stood at $251.1 million, up from $245.3 million in the prior quarter.
- The five-year high for Common Equity was $251.1 million in Q1 2026, with the low at -$101.7 million in Q4 2022.
- The 5-year median for Common Equity is $124.8 million (2024), against an average of $128.9 million.
- The sharpest annual moves came in 2022 and 2023: Common Equity plunged 53.87% in 2022, then surged 203.88% in 2023.
- Oculis Holding AG's Common Equity stood at -$101.7 million in 2022, then soared by 203.88% to $105.7 million in 2023, then dropped by 20.72% to $83.8 million in 2024, then jumped by 192.85% to $245.3 million in 2025, then grew by 2.37% to $251.1 million in 2026.
- Business Quant data shows OCS's Common Equity at $251.1 million in Q1 2026, $245.3 million in Q4 2025, and $163.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 277.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 277.51 Mn |
| Mar 31, 2026 | 251.12 Mn |
| Dec 31, 2025 | 245.32 Mn |
| Sep 30, 2025 | 163.26 Mn |
| Jun 30, 2025 | 172.84 Mn |
| Mar 31, 2025 | 180.88 Mn |
| Dec 31, 2024 | 83.77 Mn |
| Sep 30, 2024 | 109.91 Mn |
| Jun 30, 2024 | 124.76 Mn |
| Mar 31, 2024 | 90.55 Mn |
| Dec 31, 2023 | 105.66 Mn |
| Sep 30, 2023 | 119.56 Mn |
| Jun 30, 2023 | 130.34 Mn |
| Dec 31, 2022 | -101.72 Mn |
| Dec 31, 2021 | -66.11 Mn |